In other cancer types, a relevant number of different treatment options such as immunotherapy with checkpoint inhibitors; PARP inhibitors for patients with impaired homologous recombination system, PIK3CA inhibitors; and tyrosine kinase inhibitors for ALK-, ROS1-, EGFR- and MET-mutated patients have been introduced in the last 5 years for these diseases. Here, ALK is linked to cancer.